
Treatment of high-risk localized prostate cancer remains zzso The authors performed a phase 2 zzso trial of zzso zzso plus zzso before radical zzso 

zzso included any of the zzso zzso zzso zzso zzso zzso or zzso zzso zzso zzso zzso disease, any biopsy zzso score 8 to 10, and zzso score 7 with zzso disease by zzso magnetic resonance imaging zzso at zzso zzso Also, those with zzso biopsy zzso involved and either zzso score 7, zzso zzso or zzso disease were zzso Patients were treated with zzso 70 zzso every 3 weeks for 6 cycles and zzso 15 zzso every 3 weeks for 5 zzso The primary zzso was partial response by zzso zzso 

zzso patients were zzso Median age was 55 years zzso zzso zzso zzso characteristics zzso median zzso zzso zzso zzso zzso zzso zzso and zzso score 8 to 10, zzso zzso of 41 zzso patients completed all 6 zzso Grade zzso adverse events were rare, although 3 of 41 zzso experienced zzso zzso Twelve patients zzso zzso confidence zzso zzso zzso achieved a zzso reduction in tumor volume, and 9 patients zzso zzso zzso zzso achieved a zzso zzso decline in zzso zzso of the 41 patients underwent radical zzso there were no complete zzso zzso 

zzso zzso and zzso is safe, and results in reductions in both tumor volume and serum zzso in men with high-risk localized prostate zzso The role of zzso chemotherapy in prostate cancer, and zzso zzso therapy in general, requires further zzso through ongoing and planned zzso 

